A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors
ConclusionFenretinide emulsion intravenous infusion had a manageable safety profile and achieved higher plasma steady-state concentrations of the active metabolite compared to previous capsule formulations. Single-agent activity was minimal but combinatorial approaches are under evaluation.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Anemia | Bilirubin | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Oral Cancer | Skin | Study | Thrombocytopenia